| P50 | author | Ajay K Gopal | Q50211582 |
| | Oliver W Press | Q50211588 |
| P2093 | author name string | John M Pagel | |
| | Damian J Green | |
| | Shani L Frayo | |
| | Andrew J Cowan | |
| | Maria C Palanca-Wessels | |
| P2860 | cites work | Hallmarks of Cancer: The Next Generation | Q22252312 |
| | A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project | Q28239256 |
| | A decade of molecular biology of retinoic acid receptors | Q29619944 |
| | Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma | Q33364244 |
| | Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma | Q33372761 |
| | Proteasome inhibitor PS-341 (bortezomib) induces calpain-dependent IkappaB(alpha) degradation | Q33855223 |
| | Combining the endoplasmic reticulum stress-inducing agents bortezomib and fenretinide as a novel therapeutic strategy for metastatic melanoma | Q34051168 |
| | Constitutive and B-cell receptor-induced activation of STAT3 are important signaling pathways targeted by bortezomib in leukemic mantle cell lymphoma | Q34255098 |
| | Treatment-induced oxidative stress and cellular antioxidant capacity determine response to bortezomib in mantle cell lymphoma | Q35146262 |
| | Signal transduction and nuclear responses in Staphylococcus aureus-induced expression of human beta-defensin 3 in skin keratinocytes | Q35220350 |
| | Phase II study of oral capsular 4-hydroxyphenylretinamide (4-HPR/fenretinide) in pediatric patients with refractory or recurrent neuroblastoma: a report from the Children's Oncology Group | Q35511099 |
| | Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study | Q36117384 |
| | Phase II study of fenretinide (NSC 374551) in adults with recurrent malignant gliomas: A North American Brain Tumor Consortium study | Q37286891 |
| | Mantle cell lymphoma: 2013 Update on diagnosis, risk-stratification, and clinical management | Q38165907 |
| | How to manage mantle cell lymphoma. | Q39187610 |
| | The combined therapeutic effects of bortezomib and fenretinide on neuroblastoma cells involve endoplasmic reticulum stress response | Q39882024 |
| | Noxa mediates bortezomib induced apoptosis in both sensitive and intrinsically resistant mantle cell lymphoma cells and this effect is independent of constitutive activity of the AKT and NF-kappaB pathways | Q39993811 |
| | Effect of bortezomib on human neuroblastoma cell growth, apoptosis, and angiogenesis | Q40243187 |
| | Proteasome inhibitor PS-341 causes cell growth arrest and apoptosis in human glioblastoma multiforme (GBM). | Q40494554 |
| | Fenretinide enhances rituximab-induced cytotoxicity against B-cell lymphoma xenografts through a caspase-dependent mechanism. | Q40604062 |
| | N-(4-Hydroxylphenyl)retinamide (fenretinide, 4-HPR), a retinoid compound with antileukemic and proapoptotic activity in acute lymphoblastic leukemia (ALL). | Q40676167 |
| | Regulation of apoptosis induced by the retinoid N-(4-hydroxyphenyl) retinamide and effect of deregulated bcl-2. | Q42280130 |
| | Role of retinoic acid receptor overexpression in sensitivity to fenretinide and tumorigenicity of human ovarian carcinoma cells | Q42472084 |
| | A phase II study of fenretinide in patients with hormone refractory prostate cancer: a trial of the Cancer Therapeutics Research Group. | Q43191418 |
| | Synergistic effects of the fenretinide (4-HPR) and anti-CD20 monoclonal antibodies on apoptosis induction of malignant human B cells. | Q43698946 |
| | A novel mechanism by which N-(4-hydroxyphenyl)retinamide inhibits breast cancer cell growth: the production of nitric oxide. | Q44248596 |
| | Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill | Q44302226 |
| | Phase I trial and pharmacokinetics of fenretinide in children with neuroblastoma. | Q44471521 |
| | Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis | Q44484550 |
| | Proteasome inhibitors induce growth inhibition and apoptosis in myeloma cell lines and in human bone marrow myeloma cells irrespective of chromosome 13 deletion | Q44507288 |
| | The chemopreventive agent N-(4-hydroxyphenyl)retinamide induces apoptosis through a mitochondrial pathway regulated by proteins from the Bcl-2 family | Q44588827 |
| | Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004. | Q45008293 |
| | Phase II trial of fenretinide in advanced renal carcinoma | Q45296870 |
| | Phase I trial of oral fenretinide in children with high-risk solid tumors: a report from the Children's Oncology Group (CCG 09709). | Q46068154 |
| | Phase II trial of fenretinide (NSC 374551) in patients with recurrent small cell lung cancer | Q46117994 |
| | Oral fenretinide in biochemically recurrent prostate cancer: a California cancer consortium phase II trial | Q46123661 |
| | A phase I clinical and pharmacokinetic study of fenretinide combined with paclitaxel and cisplatin for refractory solid tumors | Q46611174 |
| | Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia | Q46721125 |
| | N-(4-hydroxyphenyl)retinamide inhibits invasion, suppresses osteoclastogenesis, and potentiates apoptosis through down-regulation of I(kappa)B(alpha) kinase and nuclear factor-kappaB-regulated gene products | Q46757518 |
| | Different ways to induce apoptosis by fenretinide and all-trans-retinoic acid in human B lymphoma cells. | Q46821151 |
| | Phase I and II pharmacokinetic and pharmacodynamic study of the proteasome inhibitor bortezomib in Japanese patients with relapsed or refractory multiple myeloma | Q46923545 |
| | A phase 1 study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia: a Children's Oncology Group study. | Q53735140 |
| | Effector mechanisms of fenretinide-induced apoptosis in neuroblastoma. | Q54035183 |
| | Expression of cyclins D-type in B-chronic lymphoproliferative disorders | Q62059260 |
| | In vitro anti-invasive effects of N-(4-hydroxyphenyl)-retinamide on human prostatic adenocarcinoma | Q72007106 |
| | Synthetic retinoid fenretinide is effective against a human ovarian carcinoma xenograft and potentiates cisplatin activity | Q72559517 |
| | Phase I trial of fenretinide lym-x-sorb oral powder in adults with solid tumors and lymphomas | Q83883858 |
| P4510 | describes a project that uses | ImageJ | Q1659584 |
| P433 | issue | 9 | |
| P921 | main subject | mantle cell lymphoma | Q268713 |
| P304 | page(s) | 974-983 | |
| P577 | publication date | 2015-10-01 | |
| P1433 | published in | Anti-Cancer Drugs | Q4774128 |
| P1476 | title | Bortezomib and fenretinide induce synergistic cytotoxicity in mantle cell lymphoma through apoptosis, cell-cycle dysregulation, and IκBα kinase downregulation | |
| P478 | volume | 26 | |